Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0001562180-22-007293
Filing Date
2022-10-20
Accepted
2022-10-20 16:05:38
Documents
2
Period of Report
2022-10-18

Document Format Files

Seq Description Document Type Size
1 PRIMARY DOCUMENT primarydocument.html 4  
1 PRIMARY DOCUMENT primarydocument.xml 4 7546
2 MARK VELLECA POA SEP 2018 mvelleca_sep2018poa.txt EX-24 3441
  Complete submission text file 0001562180-22-007293.txt   12540
Mailing Address 700 PARK OFFICES DRIVE SUITE 200 RESEARCH TRIANGLE PARK NC 27709
Business Address 700 PARK OFFICES DRIVE SUITE 200 RESEARCH TRIANGLE PARK NC 27709 919-213-9835
G1 Therapeutics, Inc. (Issuer) CIK: 0001560241 (see all company filings)

EIN.: 263648180 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations

Mailing Address 79 TW ALEXANDER DRIVE 4501 RESEARCH COMMONS, SUITE 100 RESEARCH TRIANGLE PARK NC 27709
Business Address
Velleca Mark A. (Reporting) CIK: 0001706847 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-38096 | Film No.: 221321301